281 Hampl et al LOH of BRCA2 and Longterm Survival 283 Table IIClinicopathological parameters and LOH data of 53 patients with primary sporadic breast cancer 17q2113q121317p13 yearsERPRBRCA1B ID: 938271
Download Pdf The PPT/PDF document "These two authors contributed equally to..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
281 *These two authors contributed equally to the work.Abbreviations: LOH, loss of heterozygosity; PCR, polymerase chainreaction; CI, confidence interval; TSG, tumor suppressor gene. Hampl et al: LOH of BRCA2 and Long-term Survival 283 Table II.Clinicopathological parameters and LOH data of 53 patients with primary sporadic breast cancer 17q2113q12-1317p13 (years)(ER/PR)BRCA1BRCA2P53MT 767inv.lob. 3pos/neg8hetn.i.MT 13 57inv.duct.2n.a.7hethethetMT 3350inv.duct.2n.a.7het n.i.MT 41 55inv.duct.3neg/neg9hethethetMT 48 50inv.duct.4neg/neg12hethetMT 54 41inv.duct.2neg/pos7LOHLOHLOHMT 6540inv.duct.4neg/neg12hethethetMT 9345inv.duct.3neg/neg11MT 10055inv.duct.2neg/neg7hetLOHLOHMT 11255inv.duct.2pos/pos6hetMT 117 50inv.duct./inv.lob.1neg/pos4n.i.hetMT 119 46inv.duct.2neg/pos7hetMT 12271inv.duct.4pos/neg10hethethetMT 12466inv.duct
.2neg/neg7LOHLOHMT 126 87inv.duct./multifoc.3neg/pos8hetMT 139 50inv.duct. 2pos/pos6hethethetMT 14379inv.duct./inv.lob.1n.a.4n.i.MT 14686inv.duct.2neg/neg7hethethetMT 14746inv.duct.2n.a.8hethethetMT15060inv.duct.3n.a.9hethethetMT 15272inv.duct.2pos/pos6hethethetMT 15752inv.duct.2pos/pos6hethetn.i.MT 18159inv.duct.2pos/pos6n.i.hethetMT 18945inv.duct.2neg/neg8hethethetMT 19956inv.duct.2pos/neg6hetMT 20755inv.duct.2pos/neg6hethetMT 208 42inv.duct./lymph.2pos/pos7hethethetMT 21550 inv.lob./multifoc./lymph.3neg/neg9hetn.i.MT 265 33inv.duct.2n.a.8hethetMT 286 46inv.duct.3neg/pos9MT 289 33inv.duct./lymph.2neg/neg8LOHLOHLOHMT 30275inv.duct.2pos/pos6hetMT 30764inv.duct.2neg/pos6hetLOHLOHMT 30858inv.duct.2pos/neg6hethethetMT 32553inv.duct.1pos/pos4hethethetMT 33054inv.duct.2n.a.7hethethetMT 333 69intraductal 2n.a.7n.i.hetMT 336 46
inv.duct./multifoc.3neg/neg10hetMT 342 49inv.duct.3pos/pos9hethethetMT 427 70inv.duct.2pos/pos6hethetMT 48250inv.duct.2pos/neg6hethethetMT 54846inv.duct.2n.a.8hethethetMT 58145inv.duct.3neg/neg10hethethetMT 62050inv.duct.4pos/pos10hetMT 62947inv.duct.2neg/neg8hethetMT 66043inv.duct.1pos/neg5hethethetMT 67736inv.duct.2n.a.8hethetMT 69254inv.duct.4pos/neg10hethetMT 83246inv.duct.2neg/neg8MT 97644inv.duct/inv.lob.2neg/neg8hethethetMT 113741inv.duct2pos/pos7hethetn.i.MT140150inv.duct2neg/neg7n.i.hethet MT 170246inv.duct.2neg/neg8n.i.hethet we attempted to correlate clinical and long-term follow-upretaining heterozygosity: at the end of our follow-up period,at least one locus had died, whereas from the 23 heterozygousMeier analysis of survival and log ranktest. From the 13only 50% of the heterozygous patients were dead. Figur
e 20.05),survivalAlthough statistically not significant, early recurrence wasLOH (Figure 3).The metastasis-free interval was 30 monthsin patients with LOH at the BRCA2 locus compared to 37&#x or ;parameters like age at diagnosis ()BRCA2 or p53 revealed that "score" (regions as additional variables for multivariate analysis usingCox proportional-hazard regression, we found that allelicwith reduced overall survival of the patients after breast0.05),was not identified as a strongerregion alone. The hazard ratio for "score" was 1.5 (95% CI,0.01) and for 13q12-13 LOH 2.3 (95% CI, 1.0-5.3;for this variable was not available. None of the additional) 285 Disease-free survival as a function of 13q12-13 LOH in 53 malignancy of the individual tumor and help to predict theunderlying alteration and inactivation of the TSG occurs. In
cell cycle progression and play an important role in DNAinstability, but do not initiate tumor growth directly. CellsBRCA1 message and protein are reduced or absent (58-62),whereas BRCA2 mRNA/protein levels seem to be elevatedguardian of the genome (gatekeeper) (74) and is known toby inducing a transient G1 arrest or inducing cell apoptosis20-40% of sporadic breast cancers (10, 13, 35, 78-80).p53 and BRCA proteins in breast tumor carcinogenesis byprotein in tumorigenesis. initiated a study of long-term follow-up of 53 breast cancerused LOH analysis because it is a fast and easy method (iflong-term survival studies are less frequent (19-22) with onlypredicts reduced postoperative mortality (49). In our group of 53 patients with primary sporadic breastaccordance with the reported data in the literature rangingfrom 20 - 63
% in BRCA1 (3, 6, 7, 92) and 20-74 % inparameters age, tumor stage (TNM) and receptor status in: 281-290(2004) 286 13Liscia DS, Morizio R, Venesio T, Palenzona C, Donadio M and14Rio PG, Pernin D, Bay JO, Albuisson E, Kwiatkowski F, DeLatour M, Bernard-Gallon DJ and Bignon YJ: Loss of15Silva JM, Gonzalez R, Provencio M, Dominguez G, Garcia JM,malignancy in breast cancer. Breast Cancer Res Treat 16Tong D, Kucera E, Schuster E, Schmutzler RK, Swoboda H,17Phelan CM, Borg A, Cuny M, Crichton DN, Baldersson T,Dale AL, Eyfjord J, Theillet C, Thompson AM and Larsson C:18Tseng SL, Yu IC, Yue CT, Chang SF, Chang TM, Wu CW and19Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R,20Hirano A, Emi M, Tsuneizumi M, Utada Y, Yoshimoto M,17p13.3, and 22q13 correlate with postoperative recurrence in21Eiriksdottir G, Barkardottir RB
, Agnarsson BA, JohannesdottirG, Olafsdottir K, Egilsson V and Ingvarsson S: High incidence22van den Berg J, Johannsson O, Hakansson S, Olsson H andwith poor prognosis in familial and sporadic breast cancer. Br J23Hampl M, Hampl JA, Schwarz P, Frank S, Hahn M, Schackert24Hampl M, Hampl JA, Reiss G, Schackert G, Saeger HD andSchackert HK: Loss of heterozygosity accumulation in primary25Frank S, Muller J, Plaschke J, Hahn M, Hampl J, Hampl M,Pistorius S, Schackert G and Schackert HK: The putative tumor26Varley JM, Swallow JE, Brammar WJ, Whittaker JL andWalker RA: Alterations to either c-erbB-2(neu) or c-myc proto-27Naidu R, Wahab NA, Yadav M and Kutty MK: Proteinpolymerase chain reaction. Int J Mol Med 28Deming SL, Nass SJ, Dickson RB and Trock BJ: C-mycand prognostic relevance. Br J Cancer29Berns EM, Klijn JG, van Staver
en IL, Portengen H,30Berns EM, Klijn JG, van Putten WL, van Staveren IL,31Bergh J: Clinical studies of p53 in treatment and benefit of32Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM,mutations in breast cancer. Cancer Res 33Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC and34Thor AD, Moore DH, II, Edgerton SM, Kawasaki ES, ReihsausE, Lynch HT, Marcus JN, Schwartz L, Chen LC and Mayall BH35Kato T, Kameoka S, Kimura T, Tanaka S, Nishikawa T and36Thompson AM, Steel CM, Chetty U, Hawkins RA, Miller WR,37Kute TE, Grondahl-Hansen J, Shao SM, Long R, Russell G and38Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M,cancer. Cancer Res 39Hamilton A and Piccart M: The contribution of molecular: 281-290(2004) 288 71Ozcelik H, To MD, Couture J, Bull SB and Andrulis IL:BRCA1 in sporadic breast cancers. Int J Cancer 72Mi
lner J, Fuks F, Hughes-Davies L and Kouzarides T: The73Futamura M, Arakawa H, Matsuda K, Katagiri T, Saji S, Miki74Lane DP: Cancer. p53, guardian of the genome. Nature75Hartmann A, Blaszyk H, Kovach JS and Sommer SS: Themolecular epidemiology of p53 gene mutations in human breast76Carson DA and Lois A: Cancer progression and p53. Lancet77Greenblatt MS, Bennett WP, Hollstein M and Harris CC:78Mackay J, Steel CM, Elder PA, Forrest AP and Evans HJ:79Nagai MA, Pacheco MM, Brentani MM, Marques LA, BrentaniRR, Ponder BA and Mulligan LM: Allelic loss on distal80Soussi T, Legros Y, Lubin R, Ory K and Schlichtholz B:81Zhang H, Somasundaram K, Peng Y, Tian H, Bi D, Weber BLstimulates its transcriptional activity. Oncogene 82Ouchi T, Monteiro AN, August A, Aaronson SA and Hanafusa83Marmorstein LY, Ouchi T and Aaronson SA: The BRCA2
gene84Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der85Ludwig T, Chapman DL, Papaioannou VE and Efstratiadis A:86Hakem R, de la Pompa JL, Elia A, Potter J and Mak TW:87Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero88Crook T, Crossland S, Crompton MR, Osin P and GustersonCrook T, Crossland S, Crompton MR, Osin P and Gusterson350(9078): 638-9, 1997.89Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J,90Gretarsdottir S, Thorlacius S, Valgardsdottir R, Gudlaugsdottir91Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J,92Schmutzler RK, Bierhoff E, Werkhausen T, Fimmers R, Speisersporadic breast carcinoma. Int J Cancer 93Tsukamoto K, Ito N, Yoshimoto M, Iwase T, Tada T, Kasumi94Kinzler KW and Vogelstein B: Cancer-susceptibility genes.Gatekeepers and caretakers. Nature : 281-290(200